Oral ciprofloxacin, a new fluorinated 4-quinolone, was evaluated in 795 patients with skin and skin structure infections. Ninety-four point one percent of the patients treated had clinical success with eradication of almost all of the offending bacteria. Ciprofloxacin has good activity against gram-positive organisms and excellent activity against gram-negative organisms. Side effects were few and not considered significant.